These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 20978104)

  • 1. Tissue distribution and characterization of drug-related material in rats and dogs after repeated oral administration of casopitant.
    Pagliarusco S; Martinucci S; Bordini E; Miraglia L; Cufari D; Ferrari L; Pellegatti M
    Drug Metab Dispos; 2011 Feb; 39(2):283-93. PubMed ID: 20978104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs.
    Miraglia L; Pagliarusco S; Bordini E; Martinucci S; Pellegatti M
    Drug Metab Dispos; 2010 Oct; 38(10):1876-91. PubMed ID: 20622044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition and metabolism of radiolabeled casopitant in humans.
    Pellegatti M; Bordini E; Fizzotti P; Roberts A; Johnson BM
    Drug Metab Dispos; 2009 Aug; 37(8):1635-45. PubMed ID: 19420128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and brain penetration of casopitant, a potent and selective neurokinin-1 receptor antagonist, in the ferret.
    Minthorn E; Mencken T; King AG; Shu A; Rominger D; Gontarek RR; Han C; Bambal R; Davis CB
    Drug Metab Dispos; 2008 Sep; 36(9):1846-52. PubMed ID: 18556439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of casopitant and its three major metabolites in dog and rat plasma by positive ion liquid chromatography/tandem mass spectrometry.
    Ferrari L; Reami D; Michi M
    J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Nov; 878(29):2974-82. PubMed ID: 20870467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism, distribution and excretion of a selective N-methyl-D-aspartate receptor antagonist, traxoprodil, in rats and dogs.
    Prakash C; Cui D; Potchoiba MJ; Butler T
    Drug Metab Dispos; 2007 Aug; 35(8):1350-64. PubMed ID: 17496205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.
    Di Fabio R; Alvaro G; Griffante C; Pizzi DA; Donati D; Mattioli M; Cimarosti Z; Guercio G; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
    J Med Chem; 2011 Feb; 54(4):1071-9. PubMed ID: 21229983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs.
    Huskey SE; Dean BJ; Doss GA; Wang Z; Hop CE; Anari R; Finke PE; Robichaud AJ; Zhang M; Wang B; Strauss JR; Cunningham PK; Feeney WP; Franklin RB; Baillie TA; Chiu SH
    Drug Metab Dispos; 2004 Feb; 32(2):246-58. PubMed ID: 14744948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Casopitant: in vitro data and SimCyp simulation to predict in vivo metabolic interactions involving cytochrome P450 3A4.
    Motta P; Pons N; Pagliarusco S; Pellegatti M; Bonomo F
    Drug Metab Dispos; 2011 Mar; 39(3):363-72. PubMed ID: 21149541
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
    Johnson BM; Adams LM; Zhang K; Gainer SD; Kirby LC; Blum RA; Apseloff G; Morrison RA; Schutz RA; Lebowitz PF
    J Clin Pharmacol; 2010 Aug; 50(8):951-9. PubMed ID: 20124517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration.
    Okuyama Y; Momota K; Morino A
    Arzneimittelforschung; 1997 Mar; 47(3):276-84. PubMed ID: 9105546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans.
    Kamel A; Obach RS; Colizza K; Wang W; O'Connell TN; Coelho RV; Kelley RM; Schildknegt K
    Drug Metab Dispos; 2010 Nov; 38(11):1984-99. PubMed ID: 20668248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy.
    Arpornwirat W; Albert I; Hansen VL; Levin J; Bandekar RR; Grunberg SM
    Cancer; 2009 Dec; 115(24):5807-16. PubMed ID: 19834961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absorption, distribution, metabolism, and excretion of N,N-diethyl-M-toluamide in the rat.
    Schoenig GP; Hartnagel RE; Osimitz TG; Llanso S
    Drug Metab Dispos; 1996 Feb; 24(2):156-63. PubMed ID: 8742226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
    Herrstedt J; Apornwirat W; Shaharyar A; Aziz Z; Roila F; Van Belle S; Russo MW; Levin J; Ranganathan S; Guckert M; Grunberg SM
    J Clin Oncol; 2009 Nov; 27(32):5363-9. PubMed ID: 19805683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism and disposition of [14C]BMS-690514 after oral administration to rats, rabbits, and dogs.
    Hong H; Su H; Sun H; Allentoff A; Ekhato IV; Chando T; Caceres-Cortes J; Roongta V; Iyer RA; Humphreys WG; Christopher LJ
    Drug Metab Dispos; 2010 Jul; 38(7):1189-201. PubMed ID: 20363952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of casopitant, a novel NK-1 receptor antagonist, on the pharmacokinetics and pharmacodynamics of steady-state warfarin.
    Kirby LC; Johnson BM; Adams LM; Eberwein DJ; Zhang K; Murray SC; Lates CD; Blum RA; Morris SR
    J Clin Pharmacol; 2010 May; 50(5):566-75. PubMed ID: 20220045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel and integrated approach for the identification and characterization of drug-induced cardiac toxicity in the dog.
    Casartelli A; Lanzoni A; Comelli R; Crivellente F; Defazio R; Dorigatti R; Fasdelli N; Faustinelli I; Pagliarusco S; Tontodonati M; Cristofori P
    Toxicol Pathol; 2011 Feb; 39(2):361-71. PubMed ID: 21422262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism, pharmacokinetics, and excretion of the substance P receptor antagonist CP-122,721 in humans: structural characterization of the novel major circulating metabolite 5-trifluoromethoxy salicylic acid by high-performance liquid chromatography-tandem mass spectrometry and NMR spectroscopy.
    Colizza K; Awad M; Kamel A
    Drug Metab Dispos; 2007 Jun; 35(6):884-97. PubMed ID: 17360832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of radio-labeled N-Acetyl-L-Cysteine in Sprague-Dawley rats and its effect on glutathione metabolism following single and repeat dosing by oral gavage.
    Arfsten DP; Johnson EW; Wilfong ER; Jung AE; Bobb AJ
    Cutan Ocul Toxicol; 2007; 26(2):113-34. PubMed ID: 17612979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.